GO:0001614 purinergic nucleotide receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001614 purinergic nucleotide receptor activity describes the molecular function of combining with a purine nucleotide and transmitting a signal across the membrane to initiate a change in cell activity.
• Purinergic nucleotide receptors are divided into P2X ionotropic receptors and P2Y metabotropic G-protein-coupled receptors, both activated by extracellular nucleotides such as ATP, ADP, UTP, and UDP.
• These receptors are expressed across the intestine, immune cells, airway epithelium, and salivary glands, where they regulate secretion, inflammation, and tissue homeostasis.
• P2Y2 receptor deletion protects mice from bacterial endotoxin and sepsis-associated liver injury and mortality, highlighting the therapeutic potential of targeting purinergic signaling.
• P2X4 is a fast and sensitive purinergic receptor that responds to ATP and plays key roles in neuropathic pain, inflammation, and lysosomal function.
• CRISPR-based knockout, knock-in, and overexpression models are essential for dissecting the causal roles of individual purinergic receptor genes in health and disease.
Description
Purinergic nucleotide receptor activity (GO:0001614) is a molecular function that enables cells to detect extracellular purine nucleotides and convert that binding event into an intracellular signal. This activity is mediated by two structurally distinct families: P2X receptors, which are ligand-gated ion channels, and P2Y receptors, which are G-protein-coupled receptors. The term encompasses the initial recognition of nucleotides such as ATP, ADP, UTP, and UDP, as well as the subsequent transmission of the signal across the membrane to initiate a change in cell activity. Researchers study this function because it is central to diverse physiological processes, including neurotransmission, immune cell recruitment, epithelial secretion, and airway clearance. In the intestine, P2Y and P2X receptors show distinct expression patterns that contribute to gut homeostasis and host defense. In salivary glands, P2Y1 nucleotide receptor activity changes during development, indicating that purinergic signaling is dynamically regulated in developing tissues. The P2Y2 receptor is a well-characterized target for nucleotide agonists, and its deletion in mice protects against sepsis-associated liver injury and mortality. These findings underscore the importance of GO:0001614 in both normal physiology and disease pathogenesis.
purinergic nucleotide receptor activity At A Glance
| GO ID | GO:0001614 |
|---|---|
| GO term | purinergic nucleotide receptor activity |
| Ontology | molecular_function |
| Synonym | P2 receptor, purinergic receptor activity, purinoceptor, purinoreceptor |
| Major function | Binding to a purine nucleotide and transmitting the signal across the membrane to initiate a change in cell activity |
| Ligand class | Purine nucleotides (e.g., ATP, ADP, UTP, UDP) |
| Receptor families | P2X ionotropic receptors and P2Y metabotropic G-protein-coupled receptors |
| Cellular context | Plasma membrane of neurons, immune cells, epithelial cells, and other tissues |
| Research relevance | Implicated in inflammation, sepsis, airway clearance, salivary gland development, and intestinal homeostasis |
What Is GO:0001614?
In simple terms, GO:0001614 purinergic nucleotide receptor activity is the ability of a membrane protein to bind a purine nucleotide, such as ATP or ADP, and then relay that signal to the inside of the cell to trigger a response. This function is defined by two coupled events: specific recognition of a purine nucleotide ligand and transmission of the signal across the membrane to initiate a change in cell activity. The term includes both ionotropic P2X receptors, which open an ion channel upon nucleotide binding, and metabotropic P2Y receptors, which activate heterotrimeric G proteins. Synonyms for this activity include P2 receptor, purinergic receptor activity, purinoceptor, and purinoreceptor.
Why Is purinergic nucleotide receptor activity Important in Cell Biology?
GO:0001614 purinergic nucleotide receptor activity is critically important because it serves as a primary mechanism by which cells sense extracellular nucleotides released during stress, injury, or inflammation. This function links nucleotide metabolism to rapid cellular responses, including ion flux, G-protein signaling, and changes in gene expression. Dysregulation of purinergic receptors contributes to sepsis-associated liver injury, inflammatory diseases, and impaired airway clearance. Understanding this activity at the molecular level enables the development of targeted therapies and the design of CRISPR models to test causal roles of individual receptors.
• P2Y2 receptor deletion protects mice from bacterial endotoxin and sepsis-associated liver injury and mortality, demonstrating a causal role in sepsis.
• Purinergic nucleotide receptors are expressed throughout the intestine, where they regulate gut homeostasis and host defense.
• Neutrophils rely on the nucleotide pathway for fast and furious immune responses, linking purinergic signaling to innate immunity.
• Nucleotide-mediated airway clearance depends on purinergic receptor activity, making it a target for respiratory diseases.
• P2Y1 nucleotide receptor activity changes during rat salivary gland development, indicating roles in organogenesis.
• P2X4 is a fast and sensitive purinergic receptor involved in neuropathic pain and inflammation.
• P2Y2 receptor agonists are actively studied as therapeutic agents for inflammatory and secretory disorders.
• Purinergic receptors are emerging targets in cancer, neurodegeneration, and metabolic diseases due to their broad expression and signaling roles.
• CRISPR screens can identify which purinergic receptor genes are essential in specific cell types and disease contexts.
• Pharmacological and genetic tools for purinergic receptors enable precise dissection of their physiological functions.
What Happens During purinergic nucleotide receptor activity?
Nucleotide release and receptor binding
In simple terms: Cells release nucleotides like ATP, and these molecules bind to purinergic receptors on the cell surface.
Purinergic nucleotide receptor activity begins when extracellular purine nucleotides, such as ATP, ADP, UTP, or UDP, become available in the extracellular space. These nucleotides can be released from damaged cells, activated platelets, or neurons, and they act as signaling molecules. The receptor, whether a P2X ion channel or a P2Y G-protein-coupled receptor, specifically recognizes and binds the purine nucleotide. This binding event is the first step in transmitting the signal across the membrane.
Conformational change and signal initiation
In simple terms: When the nucleotide binds, the receptor changes shape and starts a signal inside the cell.
Upon nucleotide binding, P2X receptors undergo a conformational change that opens a cation-permeable ion channel, allowing ions such as Na+, K+, and Ca2+ to flow across the membrane. In contrast, P2Y receptors activate heterotrimeric G proteins, which then modulate downstream effectors such as adenylyl cyclase or phospholipase C. This step represents the transmission of the signal from one side of the membrane to the other, as defined by GO:0001614. The specific downstream response depends on the receptor subtype and cell context.
Downstream signaling and cellular response
In simple terms: The signal triggers a cascade inside the cell that changes what the cell does.
Activated P2X receptors cause membrane depolarization and calcium influx, which can trigger neurotransmitter release, muscle contraction, or immune cell activation. Activated P2Y receptors modulate second messenger levels, leading to changes in ion channel activity, enzyme activity, and gene expression. In neutrophils, nucleotide signaling promotes chemotaxis and inflammatory mediator release. In airway epithelium, purinergic signaling stimulates chloride and fluid secretion, supporting mucociliary clearance. These diverse responses illustrate how a single molecular function can drive context-specific cellular outcomes.
Receptor desensitization and termination
In simple terms: After signaling, the receptor turns off to prevent overstimulation.
Purinergic receptor activity is terminated by several mechanisms, including receptor desensitization, internalization, and enzymatic degradation of extracellular nucleotides by ectonucleotidases. P2X receptors can desensitize rapidly, while P2Y receptors may undergo phosphorylation and arrestin-mediated internalization. These regulatory steps ensure that purinergic signaling is transient and tightly controlled, preventing pathological overactivation.
Key Genes Involved in GO:0001614 purinergic nucleotide receptor activity
The following genes encode the major purinergic nucleotide receptors and related proteins that mediate GO:0001614 activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| P2RY2 | P2Y2 receptor, Gq-coupled, activated by ATP and UTP | Deletion protects mice from sepsis-associated liver injury; target for nucleotide agonists |
| P2RY1 | P2Y1 receptor, Gq-coupled, activated by ADP | Activity changes during salivary gland development |
| P2RX4 | P2X4 ionotropic receptor, ATP-gated cation channel | Fast and sensitive receptor involved in pain and inflammation |
| P2RX7 | P2X7 ionotropic receptor, ATP-gated, involved in inflammasome activation | Studied in inflammation and immune cell function |
| P2RY12 | P2Y12 receptor, Gi-coupled, activated by ADP | Key role in platelet aggregation and neutrophil function |
| P2RY6 | P2Y6 receptor, Gq-coupled, activated by UDP | Expressed in intestine and immune cells |
| P2RY4 | P2Y4 receptor, activated by UTP | Expressed in intestine and epithelial tissues |
| P2RX1 | P2X1 ionotropic receptor, ATP-gated | Expressed in smooth muscle and intestine |
| P2RX2 | P2X2 ionotropic receptor, ATP-gated | Expressed in neurons and intestine |
| P2RX3 | P2X3 ionotropic receptor, ATP-gated | Expressed in sensory neurons and intestine |
| P2RX5 | P2X5 ionotropic receptor, ATP-gated | Expressed in intestine and immune cells |
| P2RX6 | P2X6 ionotropic receptor, ATP-gated | Expressed in intestine and other tissues |
| P2RY11 | P2Y11 receptor, Gs-coupled, activated by ATP | Expressed in intestine and immune cells |
| P2RY13 | P2Y13 receptor, Gi-coupled, activated by ADP | Expressed in intestine and immune cells |
| P2RY14 | P2Y14 receptor, activated by UDP-glucose | Expressed in intestine and immune cells |
| ENTPD1 | Ectonucleoside triphosphate diphosphohydrolase 1, degrades ATP/ADP | Regulates nucleotide availability for purinergic receptors |
| NT5E | Ecto-5'-nucleotidase, converts AMP to adenosine | Modulates purinergic signaling by terminating nucleotide action |
How Is purinergic nucleotide receptor activity Regulated?
Purinergic nucleotide receptor activity is regulated at multiple levels. Extracellular nucleotide availability is controlled by ectonucleotidases such as ENTPD1 and NT5E, which degrade ATP and ADP, thereby limiting receptor activation. Receptor desensitization and internalization provide negative feedback, as seen with P2X4 and other P2X receptors. In the intestine, the expression patterns of P2Y and P2X receptors are differentially regulated, suggesting tissue-specific control mechanisms. During salivary gland development, P2Y1 receptor activity changes dynamically, indicating developmental regulation. Additionally, inflammatory mediators can modulate purinergic receptor expression, linking this activity to immune responses.
purinergic nucleotide receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| P2RY2 | Sepsis-associated liver injury and mortality | Knockout mouse, overexpression in hepatocytes |
| P2RX4 | Neuropathic pain and inflammation | Knockout mouse, point-mutation knock-in |
| P2RY12 | Platelet aggregation and immune disorders | Knockout mouse, tagged knock-in |
| P2RY1 | Salivary gland developmental defects | Knockout mouse, overexpression in salivary gland cells |
| P2RX7 | Inflammasome-mediated inflammatory diseases | Knockout mouse, point-mutation knock-in |
Sepsis and liver injury
P2Y2 purinergic receptor gene deletion protects mice from bacterial endotoxin and sepsis-associated liver injury and mortality, demonstrating a causal role for purinergic nucleotide receptor activity in sepsis pathogenesis. This suggests that P2Y2 antagonists or genetic inhibition could be therapeutic in sepsis.
Inflammatory and immune disorders
Neutrophils utilize the nucleotide pathway for rapid responses, and purinergic receptors such as P2X4 and P2Y12 are involved in inflammation and immune cell recruitment. Dysregulated purinergic signaling contributes to chronic inflammatory diseases, making these receptors attractive drug targets.
Respiratory diseases
Nucleotide-mediated airway clearance depends on purinergic receptor activity, particularly P2Y2, which stimulates chloride and fluid secretion in airway epithelium. Impaired purinergic signaling may contribute to respiratory conditions characterized by mucus stasis.
Gastrointestinal and developmental disorders
P2Y and P2X receptors are differentially expressed in the intestine, where they regulate gut homeostasis. Changes in P2Y1 nucleotide receptor activity during salivary gland development suggest roles in organogenesis and potential developmental disorders.
From purinergic nucleotide receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does P2RY2 loss protect against sepsis? | P2RY2 knockout mouse |
| What is the role of P2X4 in neuropathic pain? | P2X4 knockout or point-mutation knock-in mouse |
| How does P2Y1 activity change during salivary gland development? | P2Y1 knockout or overexpression in rat salivary gland cells |
| Which purinergic receptors regulate intestinal homeostasis? | Intestine-specific knockout of P2Y and P2X genes |
| Can P2Y2 agonists improve airway clearance? | P2Y2 overexpression or knock-in in airway epithelial cells |
| What is the role of P2Y12 in neutrophil function? | P2Y12 knockout in neutrophils |
How to Study the purinergic nucleotide receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium changes | P2X/P2Y receptor activation |
| Patch-clamp electrophysiology | Ion channel currents | P2X receptor function |
| Radioligand binding | Ligand affinity and specificity | P2Y2 agonist profiling |
| RNA-seq / qPCR | Receptor gene expression | Tissue distribution of P2Y/P2X |
| CRISPR knockout | Loss-of-function effects | P2RY2 in sepsis |
| Overexpression / knock-in | Gain-of-function effects | P2Y1 in salivary gland development |
| In vivo sepsis model | Liver injury and mortality | P2Y2 knockout protection |
| Airway clearance assay | Mucociliary transport | P2Y2-mediated secretion |
Calcium imaging and ion flux assays
Calcium imaging using fluorescent dyes such as Fura-2 or Fluo-4 is widely used to measure P2X and P2Y receptor activation, as these receptors trigger calcium influx or release from intracellular stores. Patch-clamp electrophysiology directly measures ion currents through P2X channels upon nucleotide application. These methods provide real-time readouts of purinergic nucleotide receptor activity.
Ligand-binding and pharmacological profiling
Radioligand binding assays and competition experiments with selective agonists and antagonists are used to characterize nucleotide specificity and receptor affinity. For P2Y2, synthetic nucleotide agonists have been developed and profiled to understand structure-activity relationships. These approaches help identify subtype-selective compounds for therapeutic development.
Gene expression and knockout studies
Quantitative RT-PCR, RNA-seq, and in situ hybridization are used to map the expression of P2Y and P2X receptors across tissues, as demonstrated in the intestine. CRISPR knockout models allow causal testing of individual receptor genes, such as P2RY2 in sepsis. Overexpression and knock-in models can mimic gain-of-function states.
In vivo disease models
Mouse models of sepsis, inflammation, and airway disease are used to evaluate the role of purinergic receptors in vivo. For example, P2Y2 knockout mice are protected from endotoxin-induced liver injury, providing direct evidence for its pathogenic role. These models are essential for translating molecular findings into therapeutic strategies.
How CRISPR Can Be Used to Study GO:0001614 purinergic nucleotide receptor activity
Knockout
CRISPR knockout of purinergic receptor genes, such as P2RY2, enables researchers to test loss-of-function phenotypes in disease models. For example, P2RY2 knockout mice are protected from bacterial endotoxin and sepsis-associated liver injury, demonstrating a causal role. Knockout of P2X4 or P2Y12 can reveal their contributions to pain and immune responses.
Point Mutation
Point mutations can be introduced into purinergic receptor genes to mimic human polymorphisms or to disrupt specific functional domains, such as ligand-binding residues or phosphorylation sites. These models help dissect the molecular determinants of receptor activity and signaling.
Knock-in
Knock-in of tagged or fluorescently labeled purinergic receptors allows real-time visualization of receptor localization and trafficking in live cells. This approach is valuable for studying receptor internalization and desensitization.
Overexpression
Overexpression of purinergic receptors, such as P2Y2 or P2Y1, can model gain-of-function states and enhance signaling responses. This is useful for studying receptor-mediated secretion, inflammation, and developmental processes.
How EDITGENE Supports purinergic nucleotide receptor activity Research
Researchers studying purinergic nucleotide receptor activity-related genes often need to determine whether a candidate gene is causally involved in a specific physiological or pathological process. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional validation of purinergic receptor genes.
Contact EDITGENE today to design your custom CRISPR model for purinergic nucleotide receptor activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| P2RX7 Knockout HEK293 Cell Line | EDJ-KQ968 | Human | 5027 | Details Get a Quote |
| P2RX1 Knockout HEK293 Cell Line | EDJ-KQ1570 | Human | 5023 | Details Get a Quote |
| P2RX2 Knockout HEK293 Cell Line | EDJ-KQ1571 | Human | 22953 | Details Get a Quote |
| P2RX3 Knockout HEK293 Cell Line | EDJ-KQ1572 | Human | 5024 | Details Get a Quote |
| P2RX4 Knockout HEK293 Cell Line | EDJ-KQ1573 | Human | 5025 | Details Get a Quote |
| P2RX5 Knockout HEK293 Cell Line | EDJ-KQ1574 | Human | 5026 | Details Get a Quote |
| P2RX6 Knockout HEK293 Cell Line | EDJ-KQ1575 | Human | 9127 | Details Get a Quote |
| P2RX4 Knockout A-549 Cell Line | EDJ-KQ19900 | Human | 5025 | Details Get a Quote |
| P2RX1 Knockout HeLa Cell Line | EDJ-KQ21255 | Human | 5023 | Details Get a Quote |
| P2RX4 Knockout HCT 116 Cell Line | EDJ-KQ21257 | Human | 5025 | Details Get a Quote |
| P2RX4 Knockout HeLa Cell Line | EDJ-KQ21258 | Human | 5025 | Details Get a Quote |
| P2RX5 Knockout A-549 Cell Line | EDJ-KQ21259 | Human | 5026 | Details Get a Quote |
| P2RX5 Knockout HCT 116 Cell Line | EDJ-KQ21260 | Human | 5026 | Details Get a Quote |
| P2RX5 Knockout HeLa Cell Line | EDJ-KQ21261 | Human | 5026 | Details Get a Quote |
| P2RX3 Knockout HeLa Cell Line | EDJ-KQ54067 | Human | 5024 | Details Get a Quote |
Displaying Records 1 To 15 Of 28 Records
Frequently Asked Questions About purinergic nucleotide receptor activity
What is purinergic nucleotide receptor activity?
Purinergic nucleotide receptor activity (GO:0001614) is the molecular function of binding a purine nucleotide, such as ATP or ADP, and transmitting the signal across the membrane to initiate a change in cell activity.
What genes are involved in purinergic nucleotide receptor activity?
Key genes include P2RY2, P2RY1, P2RX4, P2RX7, P2RY12, and other P2X and P2Y receptor family members.
What are the synonyms for GO:0001614?
Synonyms include P2 receptor, purinergic receptor activity, purinoceptor, and purinoreceptor.
How does purinergic nucleotide receptor activity work?
Extracellular nucleotides bind to P2X ion channels or P2Y G-protein-coupled receptors, triggering ion flux or G-protein signaling that changes cell behavior.
What diseases are linked to purinergic nucleotide receptors?
They are linked to sepsis-associated liver injury, inflammatory diseases, respiratory disorders, and gastrointestinal conditions.
What is the role of P2Y2 in sepsis?
P2Y2 receptor gene deletion protects mice from bacterial endotoxin and sepsis-associated liver injury and mortality.
How can I study purinergic nucleotide receptor activity?
Methods include calcium imaging, patch-clamp electrophysiology, ligand-binding assays, RNA-seq, and CRISPR knockout models.
What is P2X4?
P2X4 is a fast and sensitive ATP-gated ionotropic purinergic receptor involved in pain and inflammation.
Are purinergic receptors expressed in the intestine?
Yes, P2Y and P2X purinergic receptors show distinct expression patterns within the intestine, where they regulate homeostasis.
How does purinergic signaling affect neutrophils?
Neutrophils use the nucleotide pathway for rapid immune responses, including chemotaxis and inflammatory mediator release.
Conclusion
GO:0001614 purinergic nucleotide receptor activity is a fundamental molecular function that enables cells to sense extracellular purine nucleotides and mount rapid, context-specific responses. Its involvement in sepsis, inflammation, airway clearance, and intestinal homeostasis underscores its broad physiological and pathological importance. CRISPR-based models, including knockout, point-mutation, knock-in, and overexpression, are powerful tools for dissecting the causal roles of individual purinergic receptor genes. EDITGENE offers comprehensive services to accelerate this research and translate findings into therapeutic strategies.
References
- 1. Arunachalam AR et al.. 2023. P2Y2 purinergic receptor gene deletion protects mice from bacterial endotoxin and sepsis-associated liver injury and mortality.. Am J Physiol Gastrointest Liver Physiol 325(5):G471-G491 PMID: 37697947
- 2. North RA et al.. 1997. Nucleotide receptors.. Curr Opin Neurobiol 7(3):346-57 PMID: 9232809
- 3. Park MK et al.. 1997. Changes in P2Y1 nucleotide receptor activity during the development of rat salivary glands.. Am J Physiol 272(4 Pt 1):C1388-93 PMID: 9142866
- 4. Rubenich DS et al.. 2021. Neutrophils: fast and furious-the nucleotide pathway.. Purinergic Signal 17(3):371-383 PMID: 33913070
- 5. Schmid A et al.. 2011. Nucleotide-mediated airway clearance.. Subcell Biochem 55:95-138 PMID: 21560046
- 6. Engevik KA et al.. 2024. Distribution of P2Y and P2X purinergic receptor expression within the intestine.. Am J Physiol Gastrointest Liver Physiol 326(2):G107-G119 PMID: 37987757
- 7. Xu P et al.. 2018. Current knowledge on the nucleotide agonists for the P2Y2 receptor.. Bioorg Med Chem 26(2):366-375 PMID: 29254895
- 8. Suurväli J et al.. 2017. P2X4: A fast and sensitive purinergic receptor.. Biomed J 40(5):245-256 PMID: 29179879
